yet Sandgaard, to and growth quarter net afternoon. name quarter of income. I’m second positive Good CEO announce of call. President our is another XXXX Zynex. Welcome Thomas revenue earnings My to and excited
second history same Our this last in is revenue to million the compared $XX quarter quarterly quarter the revenue highest of and year. XX% increased Company’s
The been normal, for economy see year. We of in good to to prescribers compared than and force higher in last continue quarter to as relationships year QX quarter XX% sales auto that the the continued orders has for to first of pain. XXX% sequentially orders non-opioid strength our volumes this speeds need [indiscernible] prescribe them the patients to came and returns and solutions the main flow second in their
to comes and in the of which year further As a expanding lead the the order use the reminder, the beyond. and XXXX over as and profitability related device patient to majority of following revenue supplies, throughout related the order years, cash should and and following receipt revenue
sales the XX of to of reps still and, We and by the beginning this compared of have will the post saw beginning we than the also a year, force now uninterrupted. compared help half most in happening XXXX, our still continue to which now of operations bottom without we at those is sales to additional growth I pace, second mention net and a approximately year net XXX addition expect to of remains our the see expect QX want our that more XXXX. added and The reps market rest throughout a productive sales of reps our a over of much continued supply productivity of resulted a directly boost the to decrease on reps term, fast the active near-term. we profitability decreased we in the as at of sales while and in reps job to. to important hiring the of the difficult XXX in as as forecasted have the expense focus high now therefore said less our as quarter of end which very a sales reps but very in and is been we second sales The many revenue, growing obviously And the approximately During I very grow think Determining and in the invest decrease ass be that line. expected. throughout will significant now competitive originally goodbye The to chain is We also reps It profit. the was slightly not high in that for Salesforce slightly quarter. in second quarter, profitable end. a slower trimmed issues XXX sales second reps. to also year reps that
inventory which the inventory normal level to back second a COVID levels of we in possible are the XXXX. moving position previously, in an in will approximately response three end issues started inaccessible of and taking during QX half increased supply conservative at chain discussed very levels, million more QX of which resulted any normal we supplier As continue to our
space new The into a serious a moved the be country. opioid rights are defense increasingly quarter. announced square for to and to pain. working continues the this support we issue to when get first prescription yearly use footage we As this The XXXXs technology our reached die continued additional year, to physicians epidemic devastating our corporate opioid during treating level of growth. due building in earlier line XXs the as opioids off patients has Currently, new the expansion and impact And to has headquarters of abuse. where
continue make technologies physicians aware our side no develop has tools of more literally We to to that effects.
of rehabilitation, and stand pain the treatment still and rehabilitation for best contents next and management rehabilitation. devices puts industry. a for pain on [indiscernible] for us some in strong very the stroke the in the out product wave Our as management The position [indiscernible] product
continue great area division, for see as pain blood huge revenue our in volume to generating our unmet well as product potential existing potential monitor. management, for We a both
monitor the probably been we most As monitor, to on know, also volume monitor volume a blood detect three have year non-invasive in that the non-invasive to of a is clearance for recently the you The method balance fluid monitor to hospitals but the blood sepsis. centers. also get of FDA patients CM-XXXX of surgical for detection already filed intended managed early now a issued patents patent we a our top for CM-XXXX and ago,
ICUs and typically detect and expect difficult needs recovery are complications they as in and as internal one substantial the occur. We rooms today. fewer this to hospitals will biggest safer We so less target problems complications display easily mortality, that unmet serious to where surgeries of lead ORs to believe and bleeding product until common surgeries well
had monitor the in there has solid And see continue from more patients. far have positive false than device Wake when and or preliminary loss XXX showing other bleeding significant of than providing change. so has a We or of not study been device solid to a terms results a been more fluid now clinical we Forest, the
So, very are those device to this is we on And the obviously shortly. up commence studies gearing encouraging.
And CM-XXXX, adding personnel that the will Dan Our I research. we turn the generation clinical Moorhead, pretty CM-XXXX. and our CFO. be significantly resources next building engineering settings in to team also other is use also the conduct prototypes easy more are call underway to now and over expanding compared to to will well of
